Document:

MDCO-12-31-13-Ex-10.5

Exhibit 10.5

Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Double asterisks denote omissions.

SECOND AMENDMENT TO GLOBAL COLLABORATION AGREEMENT

THIS SECOND AMENDMENT TO GLOBAL COLLABORATION AGREEMENT (this “Second Amendment”) is made and entered into as of the    ___ day of December, 2013 (the “Second Amendment Effective Date”), by and between AstraZeneca LP, a Delaware limited partnership (“AstraZeneca”), and The Medicines Company, a Delaware corporation (“MDCO”). 
WHEREAS, AstraZeneca and MDCO are parties to that certain Global Collaboration Agreement dated April 25, 2012 as amended by First Amendment to Global Collaboration Agreement dated as of July 24, 2012 (as so amended, the “Agreement”); and
WHEREAS, AstraZeneca and MDCO wish to amend the Agreement in accordance with the terms of this Second Amendment.
NOW, THEREFORE, in consideration of the mutual covenants and promises contained in this Second Amendment and other good and valuable consideration, AstraZeneca and MDCO agree as follows: 
		
	1.1.
	Definitions. 

		
	1.2.
	All capitalized terms not otherwise defined in this Second Amendment shall have the definitions provided in the Agreement.

		
	1.3.
	The following terms shall have their indicated meanings when used in this Second Amendment:

		
	1.3.1.
	“IHT Actuals” means, with respect to any Period, the number of tablets of the Product sold in Target Hospitals during such Period as determined by reference to AstraZeneca chargeback data and data provided by IMS Health Incorporated (or its successor) for the Product for such Period.

		
	1.3.2.
	“IHT Target” means, with respect to any Period, the target number of tablets of the Product to be sold in Target Hospitals during the Contract Quarters in such Period, as the same may be decreased (but not increased) by AstraZeneca from time to time.

		
	1.4.
	Amendments.  The following amendments to the Agreement shall apply to all Periods commencing after the end of Period 3:

		
	1.5.
	Sections 4.1 (a), 4.3, 4.10 and 4.11 of the Agreement are deleted in their entirety.

2.2 Section 7.1 (b) of the Agreement is deleted and the following is substituted therefor:
“Beginning with the Contract Quarter beginning January 1, 2014 and with respect to each Contract Quarter thereafter during the Detailing Term, AstraZeneca shall pay to MDCO three million seven hundred fifty thousand dollars ($3,750,000) (each, a “Contract Quarter Detail Fee”) within thirty (30) days after the end of each such Contract Quarter.”
		
	2.3 
	Sections 7 (c) through (e) of the Agreement are deleted and the following is substituted therefor:

“(c) Not later than the last day of the first month of each Contract Quarter, beginning with the Contract Quarter commencing on January 1, 2014, AstraZeneca and MDCO shall agree in writing on the IHT Target for such Contract Quarter.  (For example, the Parties shall agree on the IHT Target for the first Contract Quarter in Period 4 by January 31, 2014.)  If AstraZeneca and MDCO do not agree on the IHT Target by the last day of the first month of each such Contract Quarter, then AstraZeneca will establish the IHT Target for such Contract Quarter, which IHT Target will be consistent with the target used in determining incentive compensation for AstraZeneca’s Brilinta brand team for such Contract Quarter.
(i)    Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the first Contract Quarter of Period 4 ([**]), as follows: 
	
		
	If IHT Actuals for the first Contract Quarter of Period 4 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

2

For clarity, AstraZeneca shall not pay any additional amount with respect to the first Contract Quarter of Period 4 if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

(ii)     Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the second Contract Quarter of Period 4 ([**]), as follows: 
	
		
	If IHT Actuals for the second Contract Quarter of Period 4 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the second Contract Quarter of Period 4 if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

(iii)      Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the first Contract Quarter ([**]) of Period 5, if any, as follows: 
	
		
	If IHT Actuals for the first Contract Quarter of Period 5 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

3

For clarity, AstraZeneca shall not pay any additional amount with respect to the first Contract Quarter of Period 5, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

(iv)      Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the second Contract Quarter ([**]) of Period 5, as follows: 
	
		
	If IHT Actuals for the second Contract Quarter of Period 5 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the second Contract Quarter of Period 5, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.
.
(v)      Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the first Contract Quarter ([**]) of Period 6, if any, as follows: 
	
		
	If IHT Actuals for the first Contract Quarter of Period 6 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the first Contract Quarter of Period 6, if any, if IHT Actuals 

4

for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

(vi)      Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the second Contract Quarter ([**]) of Period 6, if any, as follows: 
	
		
	If IHT Actuals for the second Contract Quarter of Period 6 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the second Contract Quarter of Period 6, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

(vii)  Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the first Contract Quarter ([**]) of Period 7, if any, as follows: 
	
		
	If IHT Actuals for the first Contract Quarter of Period 7 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the first Contract Quarter of Period 7, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

5

(viii)    Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the second Contract Quarter ([**]) of Period 7, as follows: 
	
		
	If IHT Actuals for the second Contract Quarter of Period 7 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the second Contract Quarter of Period 7, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

(ix) Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the first Contract Quarter ([**]) of Period 8, if any, as follows: 
	
		
	If IHT Actuals for the first Contract Quarter of Period 8 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the first Contract Quarter of Period 8, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.

6

(x)    Not later than [**], AstraZeneca shall pay to MDCO an additional amount with respect to the second Contract Quarter ([**]) of Period 8, if any,, as follows: 
	
		
	If IHT Actuals for the second Contract Quarter of Period 8 are:
	The payment amount shall be:

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than [**]% of the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than [**]% of the IHT Target for such Contract Quarter but less than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

	Equal to or greater than the IHT Target for such Contract Quarter
	[**] dollars ($[**])

For clarity, AstraZeneca shall not pay any additional amount with respect to the second Contract Quarter of Period 8, if any, if IHT Actuals for such Contract Quarter are less than [**]% of the IHT Target for such Contract Quarter.”

2.4.  An amended Target Hospital list is annexed to this Second Amendment.

2.5  Section 16.2 (h) of the Agreement is deleted and the following is substituted therefor:

“If IHT Actuals for Period 4 are less than the IHT Target for Period 4, AstraZeneca may terminate this Agreement immediately on written notice to MDCO; provided that such notice, if given, must be given not later than ten (10) days after the delivery to MDCO of the IHT Actuals for the Territory for the last Contract Quarter of the Period.”

2.6.  Section 16.2 (i) of the Agreement is deleted and the following is substituted therefor:

“If IHT Actuals for Period 4 are equal to or greater than the IHT Target for Period 4, MDCO may terminate this Agreement immediately on written notice to AstraZeneca; provided that such notice, if given, must be given not later than ten (10) days after the delivery to MDCO of the IHT Actuals for the Territory for the last Contract Quarter of Period 4.”

2.7.  Section 16.3 (c) of the Agreement is deleted and the following is substituted therefor:

7

“If (i) AstraZeneca terminates this Agreement pursuant to Section 16.2(j), and (ii) IHT Actuals for Period 6 are equal to or greater than the IHT Target for Period 6, the Parties acknowledge and agree that such a termination will cause MDCO to suffer damages in an amount that is uncertain, not readily ascertainable and incapable of accurate calculation resulting from (A) the efforts and resources expended by MDCO in performance and contemplation of future performance under this Agreement and (B) MDCO’s forgoing other commercial opportunities because of this Agreement.  On this basis, the Parties further acknowledge and agree that in the event of such a termination, if and only if IHT Actuals for the Period 6 are equal to or greater than the IHT Target for Period 6 AstraZeneca shall pay to MDCO an amount equal to five million dollars ($5,000,000) (the “Fourth Year Termination Fee”).  The Parties acknowledge that the Fourth Year Termination Fee has been agreed upon, after negotiation, as a reasonable estimate of an amount to compensate MDCO for the efforts and resources expended and opportunities foregone by MDCO.  The Fourth Year Termination Fee shall be MDCO’s sole and exclusive remedy in respect of a termination by AstraZeneca pursuant to Section 16.2(j) if IHT Actuals for Period 6 are equal to or greater than the IHT Target for Period 6, and the Fourth Year Termination Fee is, therefore, not a penalty but rather constitutes liquidated damages in a reasonable amount that will compensate MDCO for the efforts and resources expended and opportunities foregone by MDCO.  For clarity, AstraZeneca’s termination of this Agreement pursuant to Section 16.2(j) shall not constitute a breach of this Agreement, and AstraZeneca shall have no obligation to pay the Fourth Year Termination Fee if IHT Actuals for Period 6 are less than the IHT Target for Period 6.”
		
	1.6.
	No Other Changes. Except as explicitly set forth in this Second Amendment, no amendment or modification to the Agreement is made hereby.

		
	1.7.
	Counterparts; Facsimile Execution. This Second Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument.  An executed signature page of this Second Amendment delivered by facsimile transmission or by electronic mail in “portable document format” (“.pdf”) shall be as effective as an original executed signature page.

Remainder of page left blank. Signature page follows.

8

IN WITNESS WHEREOF, each of the Parties has caused this Second Amendment to be executed by its duly authorized officers as of the Second Amendment Effective Date.
AstraZeneca LP

By:  /s/ illegible    
Name:  
Title: 

The Medicines Company

By:/s/ Brent Furse    
Name:  Brent Furse
Title:  Senior Vice President, Chief Customer Officer

9

Target Hospital List

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. A total of 39 pages were omitted. [**]

10Exhibit 10.10

[DATE]

[First_Name] [Last_Name]

Dear [First Name]:

Congratulations!  At the recent Board of Directors meeting the AMCOL Compensation Committee approved a grant to you of an award under AMCOL's 2010 Long-Term Incentive Plan in the form of Non-Qualified Stock Options (NQSOs).  The details of your specific award are as follows:

	
Date of Award (Grant Date):

	
 

	
 

	
 

	
Total Number of NQSOs:

	
 

	
Grant Price (Closing Price on Grant Date):

	
 

	
Expiration Date (10-Year Life):

	
 

	
Vesting Schedule:

	
33% per year

(Fully vested on ___)

This award, including NQSOs, is being granted under the 2010 Long-Term Incentive Plan document and related Addendum.  To view these Plan documents as well as Frequently Asked Questions about the types of awards granted under this Plan please refer to the Company's intranet site (Click here or type this URL into your internet browser https://amcol.securespsite.com/ and click on Human Resources / Stock Plans).

Administrative services in support of our Long-Term Incentive Plans are provided by Merrill Lynch.  This grant information will be added to your online records and HR will notify you when these award details are available for viewing on Merrill Lynch's Benefits OnLine site (www.benefits.ml.com).

While no one can predict the future, the objective is that these stock awards will provide you with the opportunity to own AMCOL stock and share in the Company's growth. You play a key role in the success of the company, and if we meet our expectations in the years ahead, this award could create real financial value for you.

Please be aware that financial gains on Non-Qualified Stock Options will be taxable upon exercise.  Please review Plan documents for specific tax implications.

If you have additional questions about this award, please contact me at 847-851-1658 (ed.mccann@amcol.com) or Oksana Waters at 847-851-1664 (oksana.waters@amcol.com).

Sincerely,

/s/ Ed McCann

Ed McCann

Vice President, Human Resources

AMCOL INTERNATIONAL CORPORATION

ADDENDUM TO NON-QUALIFIED STOCK OPTION AGREEMENT

PURSUANT TO 2010 LONG-TERM INCENTIVE PLAN

1.            This Addendum is attached to and made a part of a Stock Option Agreement granted pursuant to the AMCOL International Corporation (the "Company") 2010 Long-Term Incentive Plan (the "Plan").  The capitalized terms used herein shall have the meanings set forth in the Plan unless otherwise defined herein or unless the context shall require otherwise.

2.            In order to exercise the Options granted hereunder, the Optionee must provide Merrill Lynch through its Benefits OnLine System, or another successor system, notice of the number of shares with respect to which option rights are being exercised and by paying in full the option price of the shares at the time being acquired and any applicable taxes.  The date of exercise shall be deemed to be the date of receipt of the notice and payment for the shares being purchased.  The Optionee shall have none of the rights of a stockholder with respect to shares covered by such Options until the Optionee becomes record holder of such shares.

3.            Nothing herein contained shall confer on the Optionee any right with respect to continuation of employment by the Company of its subsidiaries, or interfere with the right of the Company or its subsidiaries to terminate at any time the employment of the Optionee, or, except as the shares of Common Stock actually delivered, confer any rights as stockholder upon the holder hereof.

4.            Each of the Options granted hereunder will become exercisable by the Optionee in accordance with the following vesting schedule:

 

	
Number of Years Since Award Date

	
Vested %

	
Fewer than one

	
None

	
One but fewer than two

	
33%

	
Two but fewer than three

	
66%

	
Three or more

	
100%

 

However, all Options granted hereunder will become exercisable, notwithstanding the above schedule, if: (1) the Optionee retires on or after attaining age 65; (2) the Optionee retires on or after attaining age 55 with the consent of the Company; (3) the Optionee retires on or after incurring a total and permanent disability (as determined by the Company); or (4) the Optionee dies.  If the Optionee terminates employment with the Company for any other reason, the Optionee will forfeit any Options that are not yet vested. Notwithstanding anything stated in this Stock Option Agreement to the contrary, all Options will become vested and exercisable upon the effective date of a "change in control" and will remain exercisable during the thirty (30) day period commencing on the effective date of such change in control subject to termination in accordance with Sections 5(ii)-(iv) of this Addendum.

5.            The Options granted hereunder shall expire on the earliest of:

		(i)	the date on which they are forfeited, under the provisions of Section 4 herein;

		(ii)	ten (10) years from the Award Date;

		(iii)	three (3) months after the Optionee's termination of employment with the Company and its subsidiaries for any reason other than death; or

		(iv)	twelve (12) months after the Optionee's death.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00227-of-00352.parquet"}]]